- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eyepoint Pharmaceuticals Inc (EYPT)
The Eyepoint Pharma share price today is 13.200, view NASDAQ EYPT stock exchange data. Track the latest Eyepoint Pharma share price with real-time updates on EYPT stock performance including market cap, day range, 52-week range and dividend yield. Access EYPT charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.890
13.430
52 wk Range
5.300
19.110
Earnings results expected in 5 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.89013.430
52 wk Range
5.30019.110
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EYPT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
37.167
Upside
+181.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 8K Eyepoint Pharmaceuticals Inc For: 20 March
- Investing.com
- Form 8K Eyepoint Pharmaceuticals Inc For: 20 March
- Investing.com
- Form 4 Eyepoint Pharmaceuticals Inc For: 16 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
Analyst Ratings
13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 37.167
(+181.57% Upside)
Eyepoint Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- EyePoint reported Q4 2025 EPS of -$0.81, missing analyst estimates of -$0.75 by 8%, with revenue plunging 94.8% to $0.6M year-over-year.
- Revenue decline driven by completion of deferred revenue recognition from prior licensing agreement; operating expenses rose 24.6% to $71M.
- Net loss widened to $68M from $41M in Q4 2024 as company invests heavily in DURAVYU clinical trials for retinal disease treatment.
- Cash position of $306M provides runway through Q4 2027; company targeting NDA submission for DURAVYU with key clinical milestones ahead.
- Stock fell 1.26% in pre-market to $18.09, reflecting investor concerns over widening losses and continued negative EPS forecast for FY2026.
Last Updated: 04-03-2026, 08:32 pm
Read Full TranscriptEarnings
Latest Release
04-03-2026
EPS / Forecast
-0.81 / -0.75
Revenue / Forecast
620K / 1.05M
Compare EYPT to Peers and Sector
Metrics to compare | EYPT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEYPTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.7x | −7.1x | −0.5x | |
PEG Ratio | 0.13 | 0.10 | 0.00 | |
Price/Book | 3.6x | 1.6x | 2.6x | |
Price / LTM Sales | 35.1x | 2.1x | 3.2x | |
Upside (Analyst Target) | 163.2% | 39.0% | 48.8% | |
Fair Value Upside | Unlock | 21.5% | 6.9% | Unlock |
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Eyepoint Pharma (EYPT) Share Price Today?
The Eyepoint Pharma share price today is 13.200.
What is the current Eyepoint Pharma (EYPT) share price and day range?
As of 01-05-2026, the Eyepoint Pharma share price is 13.200, with a previous close of 13.200. The share price has ranged from 12.890 to 13.430 today, while the 52-week range spans from 5.300 to 19.110.
What Is the Eyepoint Pharma Market Cap?
As of today, Eyepoint Pharma market cap is 1.100B.
What Is the Eyepoint Pharma (EYPT) Share Price Target?
The average 12-month share price target for Eyepoint Pharma is 37.167, with a high estimate of 68 and a low estimate of 20. 13 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +181.57% Upside potential.
What Is Eyepoint Pharma's Earnings Per Share (TTM)?
The Eyepoint Pharma EPS (TTM) is -3.167.
When Is the Next Eyepoint Pharma Earnings Date?
Eyepoint Pharma will release its next earnings report on 06-05-2026.
From a Technical Analysis Perspective, Is EYPT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Eyepoint Pharma Trade On?
Eyepoint Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Eyepoint Pharma?
The stock symbol for Eyepoint Pharma is "EYPT."
How Many Times Has Eyepoint Pharma Stock Split?
Eyepoint Pharma has split 2 times.
How Many Employees Does Eyepoint Pharma Have?
Eyepoint Pharma has 214 employees.
What Is the EYPT Premarket Price?
EYPT's last pre-market stock price is 13.230. The pre-market share volume is 1,310.000, and the stock has changed by 0.030, or 0.230%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.